Prodigiosin
Based on 3 publication(s) in Google Scholar
Prodigiosin (Prodigiosine) is a red pigment produced by bacteria as a bioactive secondary metabolite. Prodigiosin is a potent inhibitor of the Wnt/β-catenin pathway. Prodigiosin has antibacterial, antifungal, antiprotozoal, antimalarial, immunosuppressive, and anticancer properties.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.84%
- No. CAS: 82-89-3
- Fòrmula: C20H25N3O
- Peso molecular:323.43
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-10431
SB-431542TGF-β Receptor Kinase Inhibitor -
HY-13912
IWP-2Wnt Production Inhibitor -
HY-14428
ICG-001Apoptosis Inducer -
HY-10002
CalcitriolVDR Agonist -
HY-16592
Brefeldin AProtein Transport Inhibitor -
HY-13418A
DorsomorphinAMPK Inhibitor -
HY-10969
Obatoclax MesylateBcl-2 Family Inhibitor -
HY-12031A
U0126MEK1/2 Inhibitor -
HY-10407
SU 5402Tyrosine Kinase Inhibitor -
HY-B0795
MHY1485mTOR Activator -
HY-13813
BlebbistatinMyosin II Inhibitor -
HY-13912G
IWP-2 (GMP)Wnt Inhibitor (GMP)
Publications Citing Use of MedChemExpress (MCE) Prodigiosin
More
Customer Validation & Images
-
Histological Imaging/Staining
-
WB
-
RT-PCR
-
ELISA
-
IF
Ver todos los productos específicos de isoformas Parasite
More
Actividad biológica
Descripciòn
IC50 & Target
|
Plasmodium |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.077 μM
Compound: 1
|
Antiproliferative activity against A549 cell line by MTS assay
Antiproliferative activity against A549 cell line by MTS assay
|
[PMID: 16289814] |
| DLD-1 | IC50 |
0.079 μM
Compound: 1
|
Antiproliferative activity against DLD1 cell line by MTS assay
Antiproliferative activity against DLD1 cell line by MTS assay
|
[PMID: 16289814] |
| HepG2 | IC50 |
0.04 μM
Compound: 27
|
Anticancer activity against human HepG2 cells by MTT assay
Anticancer activity against human HepG2 cells by MTT assay
|
[PMID: 34128674] |
| HT-29 | IC50 |
0.173 μM
Compound: 1
|
Antiproliferative activity against HT29 cell line by MTS assay
Antiproliferative activity against HT29 cell line by MTS assay
|
[PMID: 16289814] |
| MDA-MB-231 | IC50 |
0.213 μM
Compound: 1
|
Antiproliferative activity against MDA-MB-231 cell line by MTS assay
Antiproliferative activity against MDA-MB-231 cell line by MTS assay
|
[PMID: 16289814] |
| NCI-H460 | IC50 |
0.032 μM
Compound: 1
|
Antiproliferative activity against NCI-H460 cell line by MTS assay
Antiproliferative activity against NCI-H460 cell line by MTS assay
|
[PMID: 16289814] |
| SK-OV-3 | IC50 |
1.3 μM
Compound: Prodigiosin
|
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
|
[PMID: 18922034] |
In Vitro
Prodigiosin (25-500 nM; 24 hours) treatment reduces the viability of breast cancer cells, with IC50 values at 48 h of 62.52 nM in MDA-MB-231 cells and 261.2 nM in MDA-MB-468 cells[1].
Prodigiosin (25-500 nM; 24 hours) treatment significantly reduces the levels of phosphorylated LRP6 and DVL2, active β-catenin, and total β-catenin. Prodigiosin noticeably inhibits the phosphorylation of GSK3β at Ser9 in HEK293T cells, which is indicative of an increase in GSK3β activity[1].
Prodigiosin can inhibit proliferation and induce apoptosis in breast cancer cells[1].
Prodigiosin (25-500 nM; 24 hours) treatment dose-dependently blocks Wnt signaling activated by Wnt1, Wnt3, Wnt1/LRP6, Wnt3/LRP6, and Dishevelled 2 (DVL2) in transfected HEK293T cells. Prodigiosin treatment inhibits Wnt3A-CM-induced transcription in a dose-dependent manner. Prodigiosin inhibits transcription of the SuperTopFlash reporter activated by either Wnt transfection or Wnt3A treatment[1].
When applied to cultures of chytrid fungi Batrachochytrium dendrobatidis and B. salamandrivorans, Prodigiosin causes significant growth inhibition, with MIC values of 10 μM and 50 μM, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231 and MDA-MB-468 cells
-
Concentration:10 nM, 25 nM, 50 nM, 100 nM, 250 nM, 500 nM, 1000 nM, 2500 nM, 5000 nM
-
Incubation Time:24 hours, 48 hours
-
Result:Reduced the viability of breast cancer cells, with IC50 values at 48 h of 62.52 nM in MDA-MB-231 cells and 261.2 nM in MDA-MB-468 cells.
-
Cell Line:HEK293T cells
-
Concentration:50 nM, 100 nM, 250 nM, 500 nM
-
Incubation Time:24 hours
-
Result:Significantly reduced the levels of phosphorylated LRP6 and DVL2, active β-catenin, and total β-catenin.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice injected with MDA-MB-231 cells[1]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection; twice weekly; for 3 weeks
-
Result:Significantly inhibited tumor growth in mice.
Chemical Information
-
No. CAS 82-89-3
-
Appearance Solid
-
Peso molecular 323.43
-
Fòrmula C20H25N3O
-
Color Brown to red
-
SMILES
CCCCCC1=C/C(N=C1C)=C\C2=C(OC)C=C(C3=CC=CN3)N2
-
Synonyms
Prodigiosine; NSC47147
-
Initial Source
Serratia marcescens
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nucleic Acids Res
Design and in vitro anticancer assessment of a click chemistry-derived dinuclear copper artificial metallo-nuclease. [Abstract]2025 Jan 7;53(1):gkae1250. PMID: 39777469 -
J Physiol Pharmacol
Prodigiosin improves acute lung injury in a rat model of rheumatoid arthritis via down-regulating the nuclear factor kappaB/nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 signaling pathway. [Abstract]2023 Feb;74(1). PMID: 37245232
Prodigiosin purchased from MedChemExpress. Usage Cited in: J Physiol Pharmacol. 2023 Feb;74(1). [Abstract]
HE staining disclosed the typical histological images of the lung treated with Prodigiosin (PRO) (1, 3, 5 μg/mL).
Prodigiosin purchased from MedChemExpress. Usage Cited in: J Physiol Pharmacol. 2023 Feb;74(1). [Abstract]
Western blot was performed to check the protein profiles of lung damage active markers SPA and SPD treated with Prodigiosin (PRO) (1, 3, 5 μg/mL).
Prodigiosin purchased from MedChemExpress. Usage Cited in: J Physiol Pharmacol. 2023 Feb;74(1). [Abstract]
RT-qPCR was implemented to ascertain the RNA and secretion levels of inflammatory cytokines TNF-a, IL-6, IL-1b, and MCP-1 treated with Prodigiosin (PRO) (1, 3, 5 μg/mL).
Prodigiosin purchased from MedChemExpress. Usage Cited in: J Physiol Pharmacol. 2023 Feb;74(1). [Abstract]
ELISA was implemented to ascertain the RNA and secretion levels of inflammatory cytokines TNF-a, IL-6, IL-1b, and MCP-1 treated with Prodigiosin (PRO) (1, 3, 5 μg/mL).
Prodigiosin purchased from MedChemExpress. Usage Cited in: J Physiol Pharmacol. 2023 Feb;74(1). [Abstract]
TUNEL was performed to examine the apoptosis of epithelial tissues in acute lung injury of the RA rat model treated with Prodigiosin (PRO) (1, 5 μg/mL).
-
Solvente y solubilidad
In Vitro:
DMSO : ≥ 25 mg/mL (77.30 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Wang Z, et al. Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells. Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13150-13155. [Content Brief]
[2]. Woodhams DC, et al. Prodigiosin, Violacein, and Volatile Organic Compounds Produced by Widespread Cutaneous Bacteria of Amphibians Can Inhibit Two Batrachochytrium Fungal Pathogens. Microb Ecol. 2018 May;75(4):1049-1062. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0919 mL | 15.4593 mL | 30.9186 mL | 77.2965 mL |
| 5 mM | 0.6184 mL | 3.0919 mL | 6.1837 mL | 15.4593 mL | |
| 10 mM | 0.3092 mL | 1.5459 mL | 3.0919 mL | 7.7296 mL | |
| 15 mM | 0.2061 mL | 1.0306 mL | 2.0612 mL | 5.1531 mL | |
| 20 mM | 0.1546 mL | 0.7730 mL | 1.5459 mL | 3.8648 mL | |
| 25 mM | 0.1237 mL | 0.6184 mL | 1.2367 mL | 3.0919 mL | |
| 30 mM | 0.1031 mL | 0.5153 mL | 1.0306 mL | 2.5765 mL | |
| 40 mM | 0.0773 mL | 0.3865 mL | 0.7730 mL | 1.9324 mL | |
| 50 mM | 0.0618 mL | 0.3092 mL | 0.6184 mL | 1.5459 mL | |
| 60 mM | 0.0515 mL | 0.2577 mL | 0.5153 mL | 1.2883 mL |
Prodigiosin Related Classifications
HY-100711 Related Classifications
Powered by Bioz